CN112105368A - 组蛋白修饰剂将效应t细胞重编程的用途 - Google Patents

组蛋白修饰剂将效应t细胞重编程的用途 Download PDF

Info

Publication number
CN112105368A
CN112105368A CN201980030423.9A CN201980030423A CN112105368A CN 112105368 A CN112105368 A CN 112105368A CN 201980030423 A CN201980030423 A CN 201980030423A CN 112105368 A CN112105368 A CN 112105368A
Authority
CN
China
Prior art keywords
cells
cell
teff
lymphocytes
hdaci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980030423.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·翊
J·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN112105368A publication Critical patent/CN112105368A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980030423.9A 2018-03-28 2019-03-28 组蛋白修饰剂将效应t细胞重编程的用途 Pending CN112105368A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649265P 2018-03-28 2018-03-28
US62/649,265 2018-03-28
PCT/US2019/024693 WO2019191501A1 (en) 2018-03-28 2019-03-28 Use of histone modifiers to reprogram effector t cells

Publications (1)

Publication Number Publication Date
CN112105368A true CN112105368A (zh) 2020-12-18

Family

ID=68060769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980030423.9A Pending CN112105368A (zh) 2018-03-28 2019-03-28 组蛋白修饰剂将效应t细胞重编程的用途

Country Status (8)

Country Link
US (2) US12173317B2 (https=)
EP (2) EP4722350A2 (https=)
JP (2) JP7447011B2 (https=)
KR (1) KR20200138325A (https=)
CN (1) CN112105368A (https=)
AU (1) AU2019243578B2 (https=)
CA (1) CA3094375A1 (https=)
WO (1) WO2019191501A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
KR20200138325A (ko) * 2018-03-28 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 이펙터 t 세포를 재프로그래밍하기 위한 히스톤 개질제의 용도
KR102069704B1 (ko) * 2018-05-16 2020-01-23 고려대학교 산학협력단 Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법
WO2020069377A1 (en) * 2018-09-27 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
JP7785699B2 (ja) * 2020-05-29 2025-12-15 シャンハイ ジュンセル セラピューティクス カンパニー リミテッド 腫瘍浸潤リンパ球の種細胞培地及びその使用
GB202008957D0 (en) * 2020-06-12 2020-07-29 Autolus Ltd Culture medium
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
WO2023201097A1 (en) * 2022-04-15 2023-10-19 Turn Biotechnologies, Inc. Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells
US20230355678A1 (en) * 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
RU2763795C2 (ru) * 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
KR20190033066A (ko) * 2016-06-24 2019-03-28 맥마스터 유니버시티 입양 세포 전달 및 종양붕괴 바이러스 병용 치료
KR102849343B1 (ko) 2018-03-07 2025-08-25 포세이다 테라퓨틱스, 인크. Cartyrin 조성물 및 사용 방법
KR20200138325A (ko) * 2018-03-28 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 이펙터 t 세포를 재프로그래밍하기 위한 히스톤 개질제의 용도
EP3847197A1 (en) * 2018-09-05 2021-07-14 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANJUM等: "Genetic Modification of T Cells with IL-21 Enhances Antigen Presentation and Generation of Central Memory Tumor-Specific Cytotoxic T Lymphocytes", 《J IMMUNOTHER》 *
BAE等: "Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors", 《LEUKEMIA》 *
BRITTANY等: "A critical role for TCF-1 in T-lineage specification and differentiation", 《NATURE》 *
LIAM等: "The Road to Memory: An Early Rest for the Long Journey", 《THE JOURNAL OF IMMUNOLOGY》 *
LOSCHINSKI等: "IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner", 《ONCOTARGET》 *

Also Published As

Publication number Publication date
JP7447011B2 (ja) 2024-03-11
WO2019191501A9 (en) 2020-02-06
JP2024037880A (ja) 2024-03-19
US20250145953A1 (en) 2025-05-08
WO2019191501A1 (en) 2019-10-03
EP3773626A4 (en) 2022-01-05
EP4722350A2 (en) 2026-04-08
AU2019243578A1 (en) 2020-10-15
CA3094375A1 (en) 2019-10-03
AU2019243578B2 (en) 2025-11-20
EP3773626A1 (en) 2021-02-17
KR20200138325A (ko) 2020-12-09
JP2021519087A (ja) 2021-08-10
US12173317B2 (en) 2024-12-24
US20210189337A1 (en) 2021-06-24
EP3773626B1 (en) 2026-01-28

Similar Documents

Publication Publication Date Title
US20250145953A1 (en) Use of histone modifiers to reprogram effector t cells
US12383581B2 (en) Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
US20250320306A1 (en) Methods for production of tissue resident memory-like t cells and use thereof
CN107847585B (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
WO2017189526A1 (en) Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
Rahmani et al. Natural killer cells and acute myeloid leukemia: promises and challenges
EP3982983A2 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
US20250235478A1 (en) Chimeric antigen receptor modified regulatory t cells for treating cancer
KR20240147977A (ko) 고형 종양의 치료를 위한 키메라 항원 수용체(car)를 포함하는 cd5 변형된 세포
JP2024534767A (ja) キメラ抗原受容体がん免疫療法の有効性を増強するためのＢｃｌ－２の調節
US20220168407A1 (en) Use of tumor-independent antigens in immunotherapies
Kumar Singh et al. The Immune Microenvironment in Acute Myeloid Leukemia: Mechanisms of Immune Evasion and Emerging Therapeutic Strategies
Sierro-Martínez Translational Advances in CAR-T Therapy: from clinical validation of an academic CAR-T cell to post-infusion biomarker discovery
WO2023225512A2 (en) Methods for optimizing t cell immunotherapeutic effector and memory function
WO2023240182A1 (en) Disruption of kdm4a in t cells to enhance immunotherapy
WO2021211663A1 (en) Chimeric myd88 receptors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination